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DEVELOPMENT OF PPAR-γ RECEPTOR AGONISTS AS THERAPEUTIC AGENTS
FOR DIABETES
By Ashwini Goswami, MS
A thesis submitted in partial fulfillment of the requirements for the degree of M.S. at
Virginia Commonwealth University.
Virginia Commonwealth University, 2009
Major Director: Dr. Martin K. Safo, Ph.D.
Assistant Professor, Department of Medicinal Chemistry

The peroxisome proliferator-activated receptors (PPARs) are the transcriptional
regulators of glucose, lipids and cholesterol metabolisms. It has been established that
PPAR-γ is the receptor for thiazolidinediones (TZDs) class of type II anti-diabetic drugs.
These compounds act as agonists of PPAR-γ. They may delay the development of type II
diabetes in individuals at high risk of developing the condition, and have been shown to
have potentially beneficial effects on cardiovascular risk factors. PPAR-γ receptor
activation by TZDs improves insulin sensitivity by promoting fatty acid uptake into
adipose tissue, increasing production of adiponectin (responsible for glucose regulation
and fatty acid metabolism) and reducing levels of inflammatory mediators such as tumor
necrosis factor-alpha (TNF-alpha), plasminogen activator inhibitor-1(PAI-1) and
interleukin-6 (IL-6). Our goal is to take advantage of the mode of binding of known
PPAR-γ agonists, such as Rosiglitazone to PPAR-γ to rationally design novel agonists of
xiv

PPAR-γ. Our long-term objective is to generate new and potent PPAR-γ agonists that
could be used to treat diabetes. To achieve our goal the study was divided into five specific
aims, including: Aim 1. Expression and purification of PPAR-γ ligand binding domain
(LBD). Aim 2. Molecular modeling to design PPAR-γ receptor modulators. Aim 3.
Synthesis of potential PPAR-γ receptor modulators. Aim 4. Functional studies to
determine the binding affinity of PPAR-γ receptor modulators. Aim 5. Structural studies of
PPAR-γ LBD in complex with PPAR-γ receptor modulators.
We expressed the His-tagged PPAR-γ LBD protein in Rosetta DE3 cells, and used a
one step affinity chromatography (Ni-NTA column) to obtain a significant yield of pure
protein. Using the structural features and the known binding mode of Rosiglitazone to
PPAR-γ LBD as a starting point, two classes of compounds (type-I and type-II
compounds) were designed as potential PPAR-γ agonists. These novel compounds were
rationalized to improve on the binding modes of Rosiglitazone via additional hydrogenbonding and/or hydrophobic interactions to the protein. Five type-I and II compounds were
synthesized and tested against PPAR-γ receptor for binding affinity, using fluorescent
polarization assay. The IC-50 value of the most potent compound (compound B) was
found to be ~ 7-fold lower than Rosiglitazone, significantly lower than the expected value.
It seems that unlike Rosiglitazone which has free rotatable thiazolidinedione ring that can
make optimal interactions with His323 and His449 (two critical residues that are important
for binding affinity), the thiazolidinedione ring in our compounds are fixed in one position
that may not lead to optimal contact with the protein. We are currently synthesizing
analogs of our compounds with rotatable thiazolidinedione ring for further studies. X-ray
xv

crystallographic study has been initiated to determine the binding modes of our compounds
with PPAR-γ LBD which would allow for structural modifications for improving existing
interactions and/or formation of new favorable interactions that could lead to higher
affinity and potency. We have also initiated testing of these compounds to determine their
PPAR-γ agonistic effects.

xvi

{CHAPTER I Introduction}

1. Nuclear Receptor
Nuclear receptors (NR) are a class of proteins found within the interior of cells that
regulate the expression of specific genes thereby controlling the development,
homeostasis, and metabolism of the organism. These receptors are soluble proteins that can
bind to specific DNA regulatory elements (response elements or REs) and act as cell type
and promoter-specific regulators of transcription.1,

2

In contrasts to other transcription

factors, the activity of nuclear receptors can be modulated by binding to the corresponding
ligands, which are small lipophilic molecules that easily penetrate biological membranes.
However, ligands for some of these nuclear receptors have not yet been identified. Nuclear
receptors have been implicated in many physiological processes, such as cancer, diabetes,
rheumatoid arthritis, asthma or hormone resistance syndromes.3 As discussed in more
detail below, nuclear receptors may be classified either according to mechanism or
homology.4
In general, nuclear receptors act as homo- and heterodimers by binding to REs
consisting of two copies of PuGGTCA core sequence. Many promoters whose
transcription was shown to be nuclear receptor-dependent have been reported to contain
nuclear receptor REs. There are also a great number of promoter and other gene regulatory
1

elements lacking REs but regulated by nuclear receptors through DNA-independent
protein-mediated transcriptional control.5 By virtue of this ligand-dependent activity, the
nuclear hormone receptors serve as an interface between cellular or the whole body
environment and our genome. The elucidation of the full length sequence of the first two
founding members of the family, the human glucocorticoid receptor (GR) and estrogen
receptor α (ERα) (cloned in 1985 and 1986, respectively) revealed a common domain
structure as well as homology to the viral oncogene “v-erbA”, suggesting the existence of a
receptor protein family.6 Also in 1986, the cellular homologue of v-erb was discovered to
be a receptor for thyroid hormone, indicating that ligands for the NRs are not limited to
steroid hormones. Following, receptors for mineralocorticoid, progesterone, androgen and
fat-soluble vitamins A and D were cloned, revealing extensive sequence similarity among
these lipophilic hormone receptors.7 Availability of genomic sequence information reveals
that humans encode 48 NR family members and mice encode 49 NR family members.
During the last two decades, remarkable progress has been made toward the
understanding of nuclear receptors in animal physiology, due to technological
advancement in molecular genetics, genome wide target gene identification, single
nucleotide polymorphism identification, and high throughput ligand identification. The
notion that NRs integrate complex metabolic homeostasis is supported by systematic
analyses of tissue-, time-, and stimuli-dependent NR gene expression.8
The NRs are defined by common structural motifs as depicted in Figure 1A. A highly
variable NH3-terminal region contains a ligand-independent activation domain called AF1. The central DNA-binding domain (DBD), consisting of two highly conserved zinc2

finger motifs unique to NRs, targets the receptor to specific DNA REs. Binding specificity
by various receptors is largely achieved by the spacing (the 3-4-5 rule) and the orientation
of two half-sites (direct-, inverted- or everted-repeat) (Figure 2). The hinge region confers
structural flexibility in the receptor dimers allowing a single receptor dimer to interact with
multiple RE sequences. The C-terminal ligand-binding domain (LBD) is functionally very
unique to NRs and responsible for: (1) receptor dimerization; (2) ligand recognition and (3)
cofactor interaction.

Figure 1. Schematic diagrams for a common domain structure of NRs which include N-terminal activation
function 1 (AF-1), DNA binding domain (DBD) consisting of two zinc fingers (ZF), non-conserved hingeregion (Hinge), ligand binding domain (LBD), and C-terminal AF-2 helix.8

Figure 2. Schematic diagrams for NR dimerization and DNA binding sequences. From the left, homodimeric
endocrine receptor (Palindrome RE), RXR heterodimers (Direct Repeat RE) and monomeric orphan receptor
(Half Site RE). Arrows: the consensus NR recognition sequence AGGTCA or a variant.8

2. Nuclear Receptors subtypes
The NRs can be broadly classified into three sub-groups based on their physiologic
ligands and potential functions (Figure 3). The first class comprises endocrine receptors
which act as high affinity receptors for fat-soluble hormones and vitamins (Kd = nM
3

range). This class includes receptors for the steroid hormones, thyroid hormone (thyroid
hormone receptor; TR), and vitamins A (retinoic acid receptors; RAR) and D (vitamin D
receptor; VDR), which are all essential for homeostatic control of the endocrine system.
Mechanistically, the steroid receptors function as homodimers and TR, VDR, and RAR
form heterodimers with the Retinoid X Receptor (RXR).

Human Nuclear Hormone Receptor Superfamily
Endocrine Receptor
Steroid Receptor
GR
Glucocorticoids
MR
Mineralocorticoids
PR
Progesterone
AR
Androgens
ER α,β Estrogens
Heterodimeric Receptors
TR α,β
Thyroid
hormone
RAR α,β,γ Retinoic acid
VDR
Vitamin D(bile
acid)

Adopted orphan
receptor
Lipid Sensors
PPAR α,β,γ Fatty acids
RXR α,β,γ
9cRA
LXR α,β
Oxysterol
FXR
Bile acids
PXR
Xenobiotics
Enigmatic Receptors
CAR
Androstane
HNF-4α,γ
Fatty acid
SF-1/ LRH-1
Phospholipids
ROR α,β,γ
Cholesterol
&
Retinoic acid
ERR α,β,γ
Estrogen??

Orphan Receptor
SHP
DAX-1
TLX
PNR
GCNF
TR2,4
NRA4 α,β,γ
Rev-erb α,β
COUP α,β,γ

?
?
?
?
?
?
?
?
?

Figure 3. Human NR superfamily including 48 family members. Representative natural ligands are shown at
right. Physiological importance of ligand-induced NR activation has been established for “Endocrine
Receptors” (Purple: homodimerizing steroid receptors, and Red: RXR heterodimers); “Adopted Orphan
Receptors” (Orange); “Enigmatic Adopted Orphans” (Blue); and “Orphan receptors” (Grey).8

4

The second receptor class is the adopted orphans, which were originally identified
based on sequence homology to endocrine receptors. These receptors were previously
classified as orphans as no known natural ligands were identified, but later “deorphanized” by subsequent identification of naturally occurring ligands. Identification of a
vitamin A derivative, 9-cis retinoic acid, as an endogenous high-affinity ligand for RXR
represented the first true adoption of an orphan NR and ushered in the age of “reverse
endocrinology” in which a receptor is used to discover its natural ligand.9 This class now
includes low affinity (Kd = μM range) receptors for dietary lipids and xenobiotics, which
all function as heterodimers with RXR. Some RXR heterodimers can be activated by RXR
ligands (permissive) but others cannot (non-permissive).10 Included within adopted
orphans are ‘‘enigmatic’’ adopted orphans, for which a ligand has been identified, at least
for one of the subtypes, but the nature of ligand-dependent regulation in physiology has not
been established. Receptors of this class are the most promising drug targets for metabolic
disorders as they regulate lipid and/or glucose homeostasis by controlling uptake,
synthesis, storage or clearance.
The third class of NRs comprised of true orphans whose ligand (natural or synthetic)
has not been identified. This class includes receptors which are most likely not regulated
by ligands based on the size of the ligand binding pocket and the position of AF-2 helix in
the apo-form in X-ray crystal structures (NR4A).11 Most likely they are regulated by
coactivator availability, receptor expression itself, covalent modification or a combination
of all of these. This class of orphan receptors has attracted considerable interest since they
could lead to the discovery of new endocrine regulatory systems.
5

Since transcriptional activity of many NRs can be modulated by lipophilic ligands, and
in turn NRs control fundamental processes important for metabolic and energy
homeostasis, NRs provide a powerful platform for drug discovery to treat metabolic
disease. Indeed, a number of synthetic ligands for endocrine receptors as well as adopted
orphan receptors are currently in clinical use or under clinical trial (Table 1).8 In addition
to the receptors that we described here, there are a number of orphan receptors about which
little is known. As an obesity pandemic and associated illnesses such as type-2 diabetes
and cardiovascular disease spread around the globe, particular attention has been focused
on the role of NRs in the pathophysiology and/or treatment of metabolic diseases including
the metabolic syndrome. Here, we review the current understanding of NR biology in the
context of metabolic regulation and disease.

6

Table 1. NRs associated with metabolic disease, and their synthetic ligands
Receptor (or Associated metabolic
Synthetic ligand or
Other
coactivator) disease or pathologies modulator being used
representative
to ameliorate
synthetic ligands
metabolic disease
Viceral obesity,
N/A
Dexamethasone,
GR
hyperglycemia
RU38486
Hypertension
Aldosterone antagonist
Fludrocortisone
MR
(Spironolactone,
Eplerenone)
Cardiac failure
Hypercholesterolemia
N/A
GC-1, KB-141
TRβ
Dyslipidemia
Fibrate (Gemfibrozil,
WY14643
PPARα
fenofibrate, clofibrate)
Atherosclerosis
Diabetes Mellitus,
Thiazolidinedione
FMOC-L-Leucine
PPARγ
insulin-resistant
(pioglitazone,
rosiglitazone)
Atherosclerosis
Dyslipidemia
N/A
GW501516,
PPARδ
KD3010
Atherosclerosis
Dyslipidemia
N/A
T0901317, GW3965
LXRα/β
atherosclerosis
Hypercholesterolemia
Guggulsterone
Fexaramine,
FXR
(antagonist)
GW4046
Bilary cholestasis
Chenodeoxycholic acid
(agonist)
Dyslipidemia
Bilary cholestasis,
St. John’s wort
SR12813
PXR
jaundice
(hyperforin), rifampin
Bilary cholestasis,
Yin Zhi Huang (6,7CITCO
CAR
jaundice
dimethylesculetin)
Insulin resistance
N/A
XCT790, 4ERRα/γ
hydroxytamoxifen
MODY, type I
N/A
N/A
HNF4α
Non-insulin dependent
diabetes mellitus
Mild obesity
N/A
N/A
SHP
Atherosclerosis
N/A
RORα

7

3. Estrogen Receptor
The estrogen receptor (ER) is a member of the nuclear hormone family of intracellular
receptors which is activated by the hormone 17β-estradiol (estrogen). ER functions as a
DNA binding transcription factor to regulate gene expression. However the estrogen
receptor also has additional functions independent of DNA binding.12 There are two
different forms of ER, usually referred to as α and β, each encoded by a separate gene
(ESR1 and ESR2 respectively). Hormone activated estrogen receptors form dimers, and
since the two forms are co-expressed in many cell types, the receptors may form ERα (αα)
or ERβ (ββ) homodimers or ERαβ (αβ) heterodimers.13 Estrogen receptors alpha and beta
show significant overall sequence homology, and both are composed of seven domains
from the N- to the C-terminus.
Different ligands may differ in their affinity to the alpha and beta isoforms of the
estrogen receptor. The natural ligand 17β-estradiol binds equally well to both receptors.
Another natural ligand Estrone and synthetic ligand raloxone bind preferentially to the
alpha receptor. The natural ligand Estriol and synthetic ligand genistein have more affinity
for the beta receptor. The different estrogen receptor combinations may respond differently
to various ligands which may translate into tissue selective agonistic and antagonistic
effects. The ratio of α- to β- subtype concentration has been proposed to play a role in
certain diseases.14
The concept of selective estrogen receptor modulators is based on the ability to
promote ER interactions with different proteins such as transcriptional coactivator or
corepressors. These coactivator or corepressor regulates ERs transcriptional activity by
8

affecting the chromatin structure through the acetylation or deacetylation of histones,
respectively. Estrogen receptor–mediated transcriptional activation is associated with the
recruitment of coactivators, such as AIB1, GRIP1, SRC-1, CBP, p300, and pCAF, and
subsequent histone acetylation. In contrast, antagonist-liganded ER is able to recruit
corepressors. Furthermore the ratio of coactivator to corepressor protein varies in different
tissues.15 As a consequence, the same ligand may be an agonist in some tissue (where
coactivators predominate) while antagonistic in other tissues (where corepressors
dominate). Tamoxifen, for example, is an antagonist in breast and is therefore used as a
breast cancer treatment but an ER agonist in bone (thereby preventing osteoporosis) and an
agonist in the endometrium (increasing the risk of uterine cancer).16 However the
subcellular localization and roles of this receptor is still object of controversy.

4. Peroxisome Proliferator-Activated Receptors (PPARs)
The peroxisome proliferator-activated receptors (PPARs) are another group of nuclear
receptor proteins that function as ligand-activated transcription factors regulating the
expression of genes. PPARs play essential roles in the regulation of cellular differentiation,
development, and metabolism (carbohydrate, lipid, and protein) of higher organisms.
PPAR-α (NR1C1) (Nuclear Receptor Nomenclature Committee, 1999) was first described
as a receptor that is activated by peroxisome proliferators, hence its name.17 Two
additional related isotypes, PPAR-β/δ (NR1C2) and PPAR-γ (NR1C3) were then found
and characterized. The PPAR-β/δ isotypes was called PPAR-β when it was first isolated
from a Xenopus oocyte library.18 The PPAR-γ gene was cloned from vertebrates, including
9

Xenopus sp., mouse, and humans.18-20 PPAR-β protein sequences were not highly
homologous to the Xenopus PPAR-β protein sequences, and were subsequently named
PPAR-δ when identified in the mouse.21 PPAR-β was also designated FAAR (fatty acid
activated receptor) in rats and NUC1 in humans.
In humans, four different subtypes of PPAR-γ mRNA (-γ1, -γ2, -γ3, and -γ4)
transcribed from four different promoters have been identified.22-24 Despite four distinct
mRNA subtypes, PPAR-γ is expressed as two isoforms, γ1 and γ2 that differ at their N
terminus. PPAR-γ2 is found at high levels in the different adipose tissues, whereas PPARγ1 has a broader expression pattern that extends to settings such as the gut, brain, vascular
cells, and specific kinds of immune and inflammatory.

5. Transcriptional Regulation by PPAR-γ
Differential promoter usage and alternate splicing of the gene generate three mRNA
isoforms: PPAR-γ1 and PPAR-γ3 mRNA encode the same protein product; the PPAR-γ2
isoform contains an additional 28 amino acids at its N-terminus. PPAR-γ1 exhibits
widespread expression, albeit at low levels, whilst PPAR-γ2 is highly expressed in adipose
tissue. Indeed, the receptor plays a critical role in fat cell differentiation, inducing the
expression of adipocyte-specific genes, and promoting the formation of mature lipid-laden
adipocytes.25,

26

Recent studies with mice genetically engineered to lack PPAR-γ have

confirmed its critical role in the development of both white and brown adipocytes in vivo,
and the clinical phenotypes of subjects with PPAR-γ gene mutations suggest a similar role
in the regulation of human adipose tissue mass.27-29
10

In contrast to steroid hormone receptors, which act as homodimers, transcriptional
regulation by PPARs requires heterodimerization with the retinoid X receptor (RXR;
NR2B).30,

31

This PPAR/RXR heterodimer can form in the absence of a ligand. When

activated by a ligand, it modulates transcription via binding to a specific DNA sequence
element frequently called a peroxisome proliferator response element (PPRE). PPAR and
RXR bind to the 5' and 3' half-sites of this element, respectively, and the 5'-flanking region
mediates the selectivity of binding between different PPAR isotypes.32 The transcriptional
control by PPAR/RXR heterodimers requires interaction with coregulator complexes—
either a coactivator for stimulation or a corepressor for inhibition of target gene
expression.33 Selective action of a given PPAR isotype in vivo probably results from a
complex interplay at a given time point between expression levels of each of the three
PPAR and RXR isotypes, affinity for a specific promoter PPRE, ligand and cofactor
availability, and possibly binding of other transcription factor in the vicinity of the PPRE.34
The gene transcription mechanism is similar to that of all NRs, as shown in Figure 4. 35
In general, the C-terminal A/F domain of the receptor heterodimerizes with RXR-α and the
PPAR/RXR-α complex binds to the PPRE sequence of the target gene promoters.30, 36, 37
The PPRE motif contains a characteristic 13-nucleotide sequence, AGGTCA N AGGTCA
(N – any nucleotide) that is composed of two hexanucleotides separated by one nucleotide
(this type of sequences is called DR-1). The direct repeat 1 (DR-1) sites are specifically
and almost exclusively recognized by the PPAR-γ/RXR-α heterodimer. Each component of
the heterodimer complex binds to one hexamer of the DR-1 motif. The unactivated PPARγ is associated with a corepressor that silences its transcriptional activity by the recruitment
11

of histone deacetylases, such as the NR corepressor, the silencing mediator of retinoid and
thyroid receptors (repression step). The binding of exo- or endogenous ligand to the
receptor stimulates the release of the corepressor and the recruitment of a coactivator,
which contains a protein with histone acetyl transferase (HAT) activity such as CREB
(cAMP response element binding protein) binding protein (CBP/p300) or SRC-1
(derepression step). The action of acetyltransferases leads to chromatin decondensation.
Following, the HAT complex dissociates and either transcription factors or the RNA
polymerase II initiation complex are recruited to the accessible promoter, resulting in
transcription activation of the target gene (transcription activation step). Interactions of
PPAR-γ with a coactivator or corepressor thus regulate its transcriptional activity by
affecting the chromatin structure through the acetylation or deacetylation of histones,
respectively.
It should be mentioned that both coactivators and corepressors are highly versatile and
are not selective for particular PPAR subtypes. It has been observed, for example, that all
three members of the PPAR family are subjected to transcriptional coactivation by the
PPAR-γ coactivator-1α (PGC-1α), which is highly expressed in tissues with high
mitochondrial metabolism, such as brown adipose tissue, heart, and skeletal muscle.33, 38-40
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Figure 4. Transcriptional activity of PPARs. (A) The promoter region with a PPRE, the TATA box, and the
transcription start site is located in a repressive chromatin structure. The binding of ligand to the
PPAR/RXR/corepressor complex causes the release of the corepressor from the ligand-activated PPAR/RXR
complex. (B) The activated PPAR/RXR complex binds to the PPRE, inducing structural change in
chromatin, with histone H1 released. The PPRE-bound PPAR/RXR targets a coactivator-acetyltransferase
complex to the promoter. (C) The coactivator-acetyltransferase complex acetylates the histone tails (Ac),
thereby generating a transcriptionally active structure. (D) Additional transcription factors (TF) and the RNA
Pol II initiation complex are recruited to the accessible promoter and transcription is initiated.35, 41
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6. Functional and Medicinal Roles of PPARs
As noted above, there are three different PPAR isotypes namely PPAR-α, -δ, and –γ,
which have been identified in vertebrates and have distinct pattern of distribution. PPARs
are important targets for the drugs used in the treatment of atherosclerosis, dyslipidaemia,
obesity, diabetes, and other disease caused by abnormal regulation of glucose and lipid
metabolism.
PPAR-α is distributed in tissues with high catabolic rates of fatty acids and high
peroxisomal activity, and the major role of PPAR-α is the regulation of energy
homeostasis.42 In liver, PPAR-α activates fatty acid catabolism, stimulates gluconeogenesis
and ketone body synthesis, and is involved in the control of lipoprotein assembly.43 PPARα also stimulates heme synthesis, cholesterol catabolism, attenuates inflammatory
responses, and participates in the control of amino acid metabolism and urea synthesis.
Increased fatty acid oxidation by activated PPAR-α lowers circulating triglyceride levels,
liver and muscle steatosis, and reduces adiposity, which improves insulin sensitivity.44 The
fibrate drugs such as gemfibrozil, clofibrate, and fenofibrate that are widely used to treat
hypertriglyceridemia are activators of PPAR-α. In addition, PPAR-α agonists have
demonstrated significant anti-inflammatory activities that seem to play a role in their
protective actions within the cardiovascular system.45
PPAR-δ is necessary for placental and gut development and is also involved in the
control of energy homeostasis by stimulating genes involved in fatty acid catabolism and
adaptive thermogenesis.46, 47 In addition, PPAR-δ has an important role in the control of
cell proliferation, differentiation, and survival and is involved in tissue repair.48 In animal
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models, PPAR-δ agonists retard weight increase under high-fat diet conditions and
therefore maintain insulin sensitivity probably by stimulating skeletal muscle fatty acid
metabolism and thermogenesis.40
PPAR-γ is a pivotal actor in adipose tissue differentiation and in maintaining adipocyte
specific functions, such as lipid storage in the white adipose tissue and energy dissipation
in the brown adipose tissue.49, 50 In addition, PPAR-γ is involved in glucose metabolism
through an improvement of insulin sensitivity and thus represents a molecular link between
lipid and carbohydrate metabolism. Like PPAR-α, -γ activation seems to limit
inflammation, adding to the interest in its possible role in limiting atherosclerosis and/or
diabetes.51,

52

Among the synthetic compounds that selectively activate PPAR-γ, the

thiazolidinediones (TZDs) are insulin sensitizers used to treat the hyperglycemia of type 2
diabetes.53, 54 The clinical use of these agonists and the discovery of both rare and severely
deleterious dominant-negative mutations that lead to a stereotyped syndrome of partial
lipodystrophy and severe insulin resistance, as well as more common sequence variants
with a much smaller impact on receptor function, have increased our understanding of the
functions of PPAR-γ in humans.55 Finally, growing evidence implicates PPAR-γ, as well
as the two other isotypes, in tumor development in different tissues, although whether
PPAR activation promotes or limits this process remains under debate and may depend on
specific conditions.56, 57

7. Structure of PPAR

15

All three PPAR isotypes have a protein domain organization similar to most members
of the superfamily (Figure 1A). This includes the NH3-terminal region, the central DNAbinding domain (DBD), the hinge region, and the C-terminal ligand-binding domain
(LBD). The best-characterized domains are the DBD and LBD. Although the latter is
generally less well conserved than the former, X-ray crystal structure analyses have
revealed a three dimensional fold of the PPAR LBD that is similar to other nuclear
receptors.
The N-terminal domain A/B has been relatively well conserved through evolution. The
chief fragment of this domain is α-helix fragment possessing a ligand-independent
activating function (AF-1). It has been shown that the hPPAR-γ2 isoform exhibits tenfold
higher activity than hPPAR-γ1 in the presence of insulin in ligand-independent
transcriptional activation.58 This data may imply different functions of the two isoforms
that differ only in their N-termini. So far, the role of the additional 28 amino-acid residues
at the N-terminus of the hPPAR-γ2 protein has not been explained. However, there are
some hypotheses about this fragment concerning its effect on an increase in receptor
activity.59 Furthermore, in the A/B domain is Ser112, which is subject to phosphorylation.
Since intramolecular communication between the A/B and the LBD domains is required
for ligand binding, the phosphorylation at Ser112 by mitogen-activated protein kinase
(MAPK) disrupts interdomain communication, resulting in a reduction in ligand-binding
affinity.60 Moreover, the MAPK-dependent phosphorylation of this residue in the hPPARγ2 protein inhibits its ability to promote specific gene expression and the process of
adipogenesis.61
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The C domain is the most conserved of all the functional domains. It contains two zinc
finger-like motifs that are responsible for binding of the receptor to the DNA promoter of
target genes. Each of the zinc fingers is encoded by a separate exon (2 and 3). Besides the
zinc fingers there are amino-acid motives determining the recognition of an appropriate
DNA sequence which binds the receptor. Additionally, a large part of the domain takes
part in dimerization with another nuclear receptor, RXR.
The less conserved domain D is a flexible hinge between the C and E/F domains.35
This site is also a docking domain for cofactors. In addition, it contains the nuclear
localization signal, a sequence recognized by transporting proteins, which determines
relocation of the synthesized protein from the cytoplasm to the cell nucleus. Moreover,
some of the amino acids are involved in the activities of both nearby domains, leading to
the dimerization and recognition of the target DNA sequence.

8. Ligand Binding Domain
The largest structural domain of PPAR is the LBD (E/F domain) located at the Cterminus, and responsible for the binding of a specific ligand and activation of PPAR
binding to PPREs in the target gene promoter. The PPAR LBD consists of 12 α-helices
that form the characteristic three-layer anti-parallel α-helical sandwich with a small fourstranded sheet. This structure delineates a large Y-shape hydrophobic pocket, the ligandbinding cavity, which is larger in PPARs than in other receptors.62,

63

This feature may

contribute to the ability of PPARs to bind a wide range of synthetic and natural lipophilic
compounds with an acidic head group. Comparison of the ligand-binding pocket of the
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three PPAR isotypes has revealed the following interesting characteristics.64 The PPAR-δ
ligand-binding pocket is significantly smaller than the corresponding PPAR-α and PPAR-γ
pockets, which are similar to each other in shape and size. This difference might explain
why fewer PPAR-δ ligands have been reported compared with PPAR-α and PPAR-γ and
may indicate that the size of the pocket contributes to the ligand-binding specificity of this
isotype. The PPAR-α pocket is more lipophilic than the two others, which suggests a
possible explanation for why certain potent PPAR-γ ligands do not bind PPAR-α and why
PPAR-α can bind the more lipophilic-saturated fatty acids. Finally, it is important to note
that single amino acid differences in the pockets can be major determinants of ligand
isotype selectivity.
The LBD contains a fragment called ligand- dependent activation function 2 (AF-2),
engaged in the recruitment of PPAR cofactors to assist the gene transcription processes.62,
65

Ligand-dependent activation of PPAR stabilizes the LBD in a relatively compact and

rigid structure in which helix 12 is in a confirmation that promotes binding of coactivator
proteins and thus has a critical function in the stimulation of target genes.62, 66 Examples of
coactivators are CBP/p300 and steroid receptor coactivators (SRC-1), PGC-1, RIP140,
ARA70. Usually nucleosome remodeling, for example by histone deacetylation and
repositioning, is necessary to allow formation of the transcription preinitiation complex.
Alternatively, corepressors inhibit the activity of the receptors in the absence of a ligand or
upon antagonist treatment. Examples of corepressors are SMRT and NCOR. Often, the
repressive effects depend on the recruitment of histone deacetylases, but sometimes direct
contacts with the basal transcription machinery are also possible.67, 68
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A “mouse trap” model of receptor activation has been proposed. According to this
model, helix 12, containing the conserved AF-2 core, closes the ligand binding site in
response to a bound ligand, resulting in a transcriptionally active form of the receptor.69
The recently solved X-ray structure of the PPAR-γ/RXRα LBD heterodimer in complex
with a synthetic ligand, GW409544 and two LXXLL (L, leucine; X, any amino acid)
peptides from SRC-1 revealed that the acidic head group of GW409544 forms hydrogen
bonds with either His-323 (helix 5) or Tyr-473 (the AF2 helix) within PPAR-γ. In addition,
comparison of the structures of GW409544 bound to PPAR-α and PPAR-γ, along with
mutational analysis of their LBDs, resulted in the identification of the single amino acids
which determine ligand selectivity. These are Tyr-314 in PPAR-α and His-323 in PPAR-γ,
which constitute part of the network of hydrogen-binding residues involved in the
activation of PPAR through its acidic ligands.64 It is noteworthy that the identification of a
major determinant of selectivity between PPAR-α and PPAR-γ has provided the
opportunity to design new diabetes drugs. Currently however, synthetic ligands like TZDs
and tyrosine agonists remain the most potent known activators of PPAR-γ. 70
The crystal structure of the apo-PPAR-γ LBD reveals a bundle of 13 α-helices and a
small four-stranded β-sheet (Figure 5). The PPAR-γ LBD is very similar to the overall fold
of other nuclear-receptor structures from helix 3 to the C terminus. However, PPAR-γ is
unique in its overall tertiary structure and contains an extra helix, designated H29, between
the first beta-strand and helix H3. The tertiary placement of helix H2 is different in PPARγ compared with other nuclear-receptor LBD tertiary structures, and provides easier access
for ligands. Helices H4, H5 and H8 are tightly packed between helices H1, H3, H7 and
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H10 at the top half of the LBD. This structural arrangement seems to be important in
forming the ligand-binding site: helices H3, H7 and H10 are anchored to allow them to jut
downwards and form the scaffolding for the large cavity of the ligand-binding site in
PPAR-γ. The binding cavity of the apo-PPAR-γ LBD site is T-shaped and extends from
the C-terminal helix to the β-sheet lying between helices H3 and H6. This domain is
mainly hydrophobic and is buried within the bottom half of the LBD. One region of the
domain is 20Å in length, lies between helix H3 and the β-sheet, and is parallel to helix H3.
Another cavity, which extends from the β-sheet to the C-terminal AF-2 helix and is 16 Å in
length, is orthogonal to the T-shaped cavity, behind helix H3.62
The crystal structure of PPAR-γ LBD in complex with the TZD, Rosiglitazone and coactivator, SRC-1 has been elucidated, and shows Rosiglitazone to occupy roughly 40% of
the ligand-binding site in the ternary complex (Figure 6). In general the ligand is in a Ushaped conformation, wrapping around helix H3 with its central benzene ring directly
behind H3 and the thiazolidinedione head group and pyridine ring wrapping around helix
H3. The thiazolidinedione head group makes several specific interactions with amino acids
in helices H3, H4, H10 and the AF-2 helix (Figure 6). The carbonyl groups of the TZD
form hydrogen bonds with two histidine residues, H323 and H449. Y473 in the AF-2 helix
forms a secondary hydrogen-bond interaction with H323. The partly negatively charged
nitrogen of the TZD head group is within hydrogen-bonding distance of the Y473 side
chain hydroxyl group. A buried lysine residue, K367, forms another secondary hydrogenbond interaction with the ligand mediated by residue H449. All of these primary and
secondary hydrogen-bond interactions result in a fixed conformation of the
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thiazolidinedione head group and of the participating amino acids. Next to the head group,
the sulfur atom of the thiazolidinedione ring is positioned in a hydrophobic region of the
PPAR-γ ligand-binding pocket formed by F363, Q286, F282 and L469. The central
benzene ring of the ligand occupies a very narrow pocket between C285 and M364. The
bridging oxygen atom between the benzene ring and the pyridine ring provides vital
geometry for the pyridine ring, which occupies the pocket between helix H3 and the βsheet.

9. Rationale and Hypothesis
PPAR-γ plays a vital role in adipose tissue differentiation.71 In addition, PPAR-γ is
involved in glucose metabolism through an improvement of insulin sensitivity and thus
represents a molecular link between lipid and carbohydrate metabolism.51, 72 Like PPAR-α,
PPAR-γ activation seems to limit inflammation, adding to the interest in its possible role in
limiting atherosclerosis and/or diabetes.52 Among the synthetic compounds that selectively
activate PPAR-γ, the thiazolidinediones (TZDs) are insulin sensitizers used to treat the
hyperglycemia of type 2 diabetes.53, 54, 73 TZDs have been shown to selectively stimulate
lipogenic activities in fat cells resulting in greater insulin suppression of lipolysis.74 Two of
these TZD, Rosiglitazone and Pioglitazone are clinically approved for the treatment of type
2 diabetes mellitus and offer a new approach in the pharmacologic management of this
disease. Unlike other oral antidiabetic agents, TZDs are unique because they improve
insulin sensitivity by increasing insulin-mediated glucose uptake in skeletal muscle,
suppressing hepatic glucose output and improving the secretory response of insulin in
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Figure 5. Crystal structure of the apo-PPAR-γ.62

Figure 6. Crystal structure of PPAR-γ LBD in complex with Rosiglitazone.62
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pancreatic β-cells. The findings that TZDs could form a number of reactive intermediates,
including quinones and quinone methides, led investigators to hypothesize that TZDs
hepatotoxicity was mediated by these intermediates through either a classic Glutathione
(GSH)depletion/covalent binding mechanism or via oxidative stress caused by redox
cycling of the quinone. This would potentially explain the zone 3 centrilobular necrosis
produced by TZDs in the liver as P450 activities are higher and GSH levels are lower in
this zone than in others. Quinones are also well-established cytotoxic agents and can
produce toxicity by redox cycling with molecular oxygen to produce superoxide anion
radical and subsequent oxidative stress.75
The TZDs are indicated in the United States for monotherapy and as combination
therapy with sulfonylureas, metformin and insulin for treatment of type 2 diabetes
mellitus.76, 77As monotherapies, both Rosiglitazone and Pioglitazone significantly improve
insulin sensitivity and glycemic control in type 2 diabetes mellitus patients by decreasing
plasma glucose and plasma insulin levels, thus reducing HbA1c levels from 0.5% to
1.9%.78, 79 In combination therapy with other oral diabetes medications, both Rosiglitazone
and Pioglitazone demonstrate additive effects on glycemic control compared with
monotherapy.76
After studying the crystal structure of Rosiglitazone in the binding pocket of PPAR-γ
LBD with the co-activator SRC-1,62 we decided to design novel PPAR-γ agonistic ligands
based on the mode of Rosiglitazone interactions with PPAR-γ LBD.
The objective is to take advantage of the PPAR-γ LBD binding site characteristics and
the mode of binding of known PPAR-γ agonists to rationally design novel agonists of
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PPAR-γ. The goal is to generate new and potent PPAR-γ agonists that could be used to
treat diabetes. Our working hypothesis is that these compounds will bind to PPAR-γ LBD
and exhibit agonistic effects. To achieve our goal the study was divided into five specific
aims:

Aim 1. Expression and purification of PPAR-γ LBD.
Aim 2. Molecular modeling to design PPAR-γ receptor modulators.
Aim 3. Synthesis of potential PPAR-γ receptor modulators.
Aim 4. Functional studies to determine the binding affinity of PPAR-γ receptor
modulators.
Aim 5. Structural studies of PPAR-γ LBD in complex with PPAR-γ receptor modulators.
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{CHAPTER II Experimental Methods}

1.

Expression and Purification of PPAR-γ LBD.
The plasmid containing the LBD fragment of the human PPAR-γ (residues 195-477)

and a pGEX-4T1 vector with GST gene (GE Healthcare) were digested with restriction
enzymes BamH1 and Xho1, and then run on an agarose gel. The LBD fragment and the
pGEX-4T1 vector were extracted from the gel using a Qiagen (Valencia, California) DNA
extraction kit and then ligated with T4 DNA ligase (Novagen). The ligated plasmid was
transformed into Rosetta (DE3) cells (Novagen), which were grown at 37°C in LB medium
containing 50μg/ml kanamycin and 34μg/ml chloramphenicol, and after reaching an
OD600nm of 1.0, it was induced with 1.0 mM isopropyl-β-D thiogalactopyranoside (IPTG).
Incubation was carried out in a mechanical shaker at 37°C for 18 hours (overnight). Cells
were harvested with centrifugation and broken with Avestin EmulsiFlex-C3 homogenizer.
The solution was saturated with ammonium sulfate to 20% and the precipitate discarded.
Second ammonium sulfate treatment (45% saturation) yielded a precipitate with 98% of
the activity of the lysate. Cells were collected by rapid centrifugation and resuspended in 1
X PBS (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.47 mM KH2PO4), pH 7.4, and 1
mM dithiothreitol (DTT) containing 1 mM phenylmethylsulfonyl fluoride and dialyzed
overnight against the same buffer. The GST-PPAR fusion protein was purified from the
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cell pellet using glutathione-sepharose beads, following the procedure recommended by
the manufacturer (Amersham Pharmacia Biotech). The dialyzed protein was then
centrifuged at 5,000 rpm, to remove some of the turbidity so that it does not clog the
column. The protein was loaded on to a previously equilibrated GST-column with 1 X
PBS buffer, and then washed with 200 ml of 1 X PBS buffer to remove extra non-bound
protein. For removal of the GST moiety, we digested the fusion protein with thrombin
(Pharmacia) on the column. The cleaved PPAR-γ LBD was eluted with elution buffer (50
mM Tris-HCl, 10 mM reduced glutathione), pH 8.0. The protein yield was 5mg/L
determined using Bradford assay. Due to poor expression, as well as time consuming and
labor intensive purification procedure, an alternate method was developed (see below) for
obtaining pure protein with better yield.
The plasmid containing the LBD fragment of the human PPAR-γ (residues 204-477)
amplified from a cDNA library from human fetal brain tissue (Invitrogen), was obtained
from our Brazilian collaborators, Polikarpov and colleagues, and transferred to competent
Rossetta cells (Strat-agene). The transformed cells were grown in Luria-Bertani medium
containing 50μg/ml kanamycin and 34μg/ml chloramphenicol at 37˚C. At OD600nm of 0.5,
the expression was induced by addition of 0.1 mM IPTG for 18 hours (overnight) at 25˚C.
Cells were harvested with centrifugation and broken with Avestin EmulsiFlex-C3
homogenizer. Cell lysis was performed using lysozyme treatment followed by
homogenization. After collecting the soluble fraction, the protein product was isolated in a
single purification step by immobilized metal affinity chromatography using the Ninitrilotriacetic acid (NiNTA) coloumn (Invitrogen), previously equilibrated with the
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running buffer 50 mM NaCl, 25 mM Tris-HCl, pH 8.0. The PPAR-γ LBD bearing a Histag fused to its N terminus was eluted stepwise using running buffer to which up to 200
mM imidazole had been added. After purification, 5 mM DTT was added to the buffer.
The purity of the protein was determined to be greater than 95% using SDS gel
electrophoresis.
2. Molecular Modeling to Design PPAR-γ Receptor Modulators.
A. Design:
Our purpose was to use the binding mode of Rosiglitazone in PPAR-γ LBD to design
potent agonists of this nuclear receptor. The molecular modeling program Sybyl, and the
crystallographic modeling programs TOM80 and COOT81 were used for the design studies.
The known crystal structure of PPAR-γ LBD in complex with Rosiglitazone (PDB code
2PRG) was used as the docking model.
Figures 6 and 7 show the binding of Rosiglitazone to PPAR-γ LBD (PDB code 2PRG).
The carbonyl groups of the TZDs form hydrogen-bond interactions with the side-chains
NE2 atoms of His323 and His449. The partly negatively charged nitrogen of the
thiazolidinedione moiety is within hydrogen-bonding distance of the Tyr473 side chain
hydroxyl group. The central benzene ring of the ligand occupies a very narrow pocket
between Cys285 and Met364. Binding of ligand is believed to activate a nuclear receptor
heterodimer, PPAR-γ/ RXR-α through covalent binding to Cys285 in PPAR-γ LBD.82 The
bridging oxygen atom between the benzene ring and the pyridine ring provides vital
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geometry for the pyridine ring, which occupies the pocket between helix H3 and the βsheet.
Based on the binding mode of Rosiglitazone, we reasoned that increased affinity and
agonistic activity of ligands to PPAR-γ LBD can be obtained by exploiting some potential
binding interactions as noted below.
1.

The residue, Cys285 could be utilized to make potential hydrogen-bond
interaction with the ligand.

2.

There is a hydrophobic cavity formed by Ile281, Met348, Ile341 and
Arg288 near the pyridine ring of Rosiglitazone, which can be utilized to
make hydrophobic contact with the ligand.
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Figure 7. Rosiglitazone in crystal structure with PPAR-γ LBD.
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Based on these assumptions, we identified two important parts of the Rosiglitazone
structure – the thiazolidinedione core structure and the hydrophobic agonistic side-chain as
shown in Figure 8A. Using these two identified pharmacophores, two classes of novel
compounds can be designed. We will call these type-I and type-II compounds. For the
type-I compounds, the ether bridge between the core structure and the hydrophobic side
chain is modified as an amide without extending the hydrophobic chain length. An
example of type-I compound (compound A) is shown in Figure 8B.

This class of

compounds is hypothesized to bind similarly as Rosiglitazone but with additional
hydrogen-bond interaction between the amide oxygen of the ligand and Cys285 of PPAR-γ
LBD.
For type-II compounds, in addition to replacing the ether linkage with an amide
moiety, the hydrophobic part is also extended by incorporating additional ring (isoxazole
or furan) to the phenyl substituent. An example of type-II compound (compound B) is
shown in Figure 8C. This compound is proposed to bind to increase both hydrogen-bond
and hydrophobic interactions with the protein.
B. Docking:
Using SYBYL 7.3, representative molecules of these two classes (compound A from
type-I and B from type-II) were built and energy minimized. The crystallographic structure
of PPAR-γ LBD in complex with Rosiglitazone was obtained from the Protein Data Bank
(PDB code 2PRG) and used as the target molecule for docking the minimized compounds
A and B. Prior to docking the molecules into the target, hydrogen atoms which are not part
of the 2PRG structure were added to the protein using tools within SYBYL 7.3. The added
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hydrogen atoms were energy minimized to reduce steric clashes with the protein residues
to a gradient of 0.005 using Gasteiger Hϋckel charges, a dielectric constant of 1.0, and a
gradient of 0.005Kcal/mol Å with 10,000 iterations.
This ensures the ideal position and conformation for the added hydrogen atoms. The
coordinates of all non-hydrogen atoms were not altered during the minimization and were
kept fixed.83 The individual software programs used for the studies are all incorporated in
the molecular modeling and graphic program SYBYL 7.3 (Tripos Inc) software suite.
The molecules were then manually docked into the known crystal structure of PPAR-γ
LBD using TOM and/or COOT, and then energy minimized with a subset of the active site
residues using SYBYL. A hot radius of protein-ligand subset of 6 Å, and surrounding
radius of 12 Å were used for the computation. Other conditions specified for the
minimization process include Gasteiger Hückel charges, dielectric constant of 1.0, a
gradient of 0.005 and 10,000 iterations, whereas the coordinates of all other atoms outside
the subset were kept fixed. As a control, we also energy minimized the crystallographically
bound Rosiglitazone.
Subsequently, the docked molecules were subjected to HINT (eduSoft, LC) analysis, to
analyze the interactions between the compounds and the protein. HINT uses a scoring
function that employs empirically derived parameter log Po/w (partition coefficient for 1octanol/water) - utilizing fragment rules of Hansch and Leo. 84, 85 The program calculates a
score for each interaction between various atoms of the protein and ligand, and the
cumulative score is termed as HINT score. A positive HINT score value indicates
hydropathically

favorable

contacts

(hydrogen
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bonds,

acid/base,

and

hydrophobic/hydrophobic), while negative value indicates unfavorable contacts (acid /acid,
base/base, and hydrophobic/polar). The factor log Po/w of a ligand or biological molecule is
the sum of all the hydrophobic atomic constants for that molecule, and directly correlated
with free energy. HINT score therefore reveals information not only about enthalpy but
also entropy of the bimolecular complex.83, 86, 87

3. Synthesis of Potential PPAR-γ Receptor Modulators.
1H-NMR (Proton Nuclear Magnetic Resonance) spectra were obtained on a Varian
Gemini 300 MHz spectrometer and tetramethylsilane was used as an internal standard.
Routine thin-layer chromatography (TLC) was performed on silica gel GHIF plates (250 μ,
2.5 x 10 cm; Analtech Inc., Newark, DE). Elemental analysis was performed by Atlantic
Microlab, Inc.

A. Chemical Synthesis:
Based on the above design studies, we devised three synthetic schemes, Scheme 1 - 3
to synthesize type-I and -II compounds. In scheme 1, we synthesized 5-(4-Aminobenzylidene)-thiazolidine-2,4-dione or (4), which is the common starting material for typeI and -II compounds. Scheme 2 involves synthesis of type-I compounds, including A, D,
G, H and I. Scheme 3 involves synthesis of a type-II compounds, including B, C, F, J and
K. We note that even though attempts were made to synthesize compounds G, H and I
from type-I and J and K from type-II (shown in schemes 2 and 3 in results and discussion
part), we failed to obtain the end products. The proceeding synthetic procedures are those
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for the compounds that we were able to synthesize, which are similar to the procedures
used for synthesizing the failed compounds.

a. Intermediates:
5-(4-Amino-benzylidene)-thiazolidine-2,4-dione , 4:
In scheme 1, 5-(4-Amino-benzylidene)-thiazolidine-2,4-dione or 4 was synthesized
using a two step reaction procedure.
In step 1, a mixture of 4-nitrobenzaldehyde, 1 (5.0g, 33 mmol), 2,4-thiazolidinedione,
2 (3.9 g, 33 mmol), piperidine (0.5 mL) and acetic acid (0.5 mL) in toluene (100 mL) was
heated to reflux with Dean Stark apparatus for 16 hours. The mixture was cooled in ice, the
precipitate filtered, and washed with cold toluene. The product was re-crystallized from
methanol to yield 5-(4-nitro-benzylidene)-thiazolidine-2,4-dione, 3, to yield 5.07 g (61%);
1

H NMR (CD3COCD3) δ 7.77-7.80 (m, 3H), 8.26-8.29 (m, 2H), 12.4 (br, H).
In step 2, to a stirring solution of 3 (3.0 g, 12 mmol) in ethanol (100 mL) was added tin

(II) chloride (13.6g, 60 mmol) and the mixture heated to reflux for 2 hours. The reaction
mixture was cooled and neutralized with sodium bicarbonate and the product extracted
with ethyl acetate (3 x 200 mL). The organic layer was dried (MgSO4), filtered and
evaporated at reduced pressure to yield of 1.4 g (53%); 1H NMR (CD3COCD3) δ 6.1 (br,
2H), 6.8 (d, 2H, J = 8.7 Hz), 7.4 (d, 2H, J = 8.4 Hz), 12.3 (br, H).

b. Synthesis of Type-I Compounds:
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In scheme 2, compounds A and D were synthesized as follows:
N-[4-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-phenyl]-3-phenyl-propionamide, A:
To a mixture of 4 (500 mg, 2.3 mmol), and triethylamine (0.92 mg, 9.2 mmol) in
dichloromethane (30 mL) at 0° C and under nitrogen was added hydrocinnamoyl chloride,
5 (383 mg, 2.3 mmol,) in dichloromethane (30 mL) dropwise. After stirring at the same
temperature for ten minutes, the mixture was further stirred at room temperature for 2 hr.
The mixture was washed with dilute hydrochloric acid (2 x 30 mL), and aqueous sodium
bicarbonate (2 x 30) followed by brine (30 mL). The organic layer was dried (MgSO4),
filtered and evaporated at reduced pressure to yield 500 mg (61%). 1H NMR (CD3COCD3)
δ 2.7 (t, 2H, J = 7.8 Hz), 3.0 (t, 2H, J = 7.5 Hz), 7.2 (t, H, J = 4.8 Hz), 7.3 (d, 4H, J = 6.9
Hz), 7.7 (s, H), 7.8 (d, 2H, J = 6.9 Hz). Anal. calc. for C19H16N2O3S : C, 64.76; H, 4.58; N,
7.95; Found : C, 64.50; H, 4.65; N,7.88.

N-[4-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-phenyl]-2-(pyridin-3-yloxy)-acetamide, D:
To a mixture of 4 (500 mg, 2.3 mmol), 3-pyridyloxyacetic acid or 6 (348 mg, 2.3
mmol), under nitrogen at room temperature was added 1-hydroxybenzotriazole hydrate
(HOBt) (337.5 mg, 2.53 mmol) and N-(3-dimethylaminopropyl)-N-ethylcarbodiimide
(DEC) (523 g, 2.76 mmol), in N,N-dimethylformide (DMF) and the mixture stirred
overnight. The reaction mixture was diluted with ethyl acetate (100 mL), washed with
dilute hydrochloric acid (3 x 40 mL), aqueous sodium bicarbonate (3 x 40 mL) and brine
(40 mL). The organic layer was dried (MgSO4), filtered and evaporated at reduced pressure
to yield 450 mg (55%). 1H NMR δ 4.8 (s, 2H), 7.4 (m, 2H), 7.6 (d, 2H, J = 9.0 Hz), 7.7 (s,
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H), 7.8 (d, 2H, J = 9.0 Hz), 8.2 (d, H, J = 4.8 Hz), 8.4 (d, H, J = 2.4 Hz), 10.4 (s, H), 12.5
(br, H). Anal. calc. for C17H13N3O4S : C, 57.46; H, 3.69; N, 11.82; Found : C, 57.20; H,
3.67; N, 11.69.

c. Synthesis of Type-II Compounds:

5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic

acid

[4-(2,4-dioxo-thiazolidin-5-

ylidenemethyl)-phenyl]-amide, B:
Compound B was synthesized in the same manner as D with a mixture of 4 (1.0 g, 4.6
mmol), 5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid or 7 (1.2 g, 4.6 mmol),
HOBt (675 mg, 5.06 mmol) and DEC ( 1.0 g, 5.5 mmol), to yield 1.11 g (53%). 1H NMR δ
6.9 (d, H), 7.4 (d, H), 7.8 (m, 9H), 9.8 (br, H). Anal. calc. for C22H13F3N2O4S : C, 57.64;
H, 2.86; N,6.11; Found : C, 57.64; H, 2.83; N, 5.99.

3-p-Tolyl-isoxazole-5-carboxylic acid [4-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-phenyl]amide, C:
Compound C was prepared by using same sequence as D with a mixture of 4 (1.0 g,
4.6 mmol), 3-p-Tolyl-isoxazole-5-carboxylic acid, 8 (924 mg, 4.6 mmol), HOBt (675 mg,
5.06 mmol) and DEC ( 1.0 g, 5.5 mmol,) to yield 1.024 g (55%). 1H NMR δ 2.4 (s, 3H),
7.4 (d, 2H, J = 7.5 Hz), 7.4 (s, H), 7.6 (d, 2H, J = 7.8 Hz), 7.7 (s, H), 7.8 (d, 2H, J = 7.9
Hz), 7.9 (d, 2H, J = 7.9Hz). Anal. calc. for C21H15N3O4S : C, 62.21; H, 3.73; N, 10.36;
Found : C, 62.42; H, 3.66; N, 10.19.
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5-p-Tolyl-furan-2-carboxylic acid [4-(2, 4-dioxo-thiazolidin-5-ylidenemethyl)-phenyl]amide, F:
Compound F was prepared by using same sequence as B with a mixture of 4 (1.0 g, 4.6
mmol), 5-[4-Methoxyphenyl]-2-furoic acid, 9 (990 mg, 4.6 mmol), HOBt (675 mg, 5.06
mmol) and DEC ( 1.0 g, 5.5 mmol,) to yield 1.06 g (57%). 1H NMR δ 2.4 (s, 3H), 7.1 (d,
H, J = 3.3 Hz), 7.3 (d, 2H, J = 8.4 Hz), 7.5 (d, H, J = 3.6 Hz), 7.6 (d, 2H, J = 9.0 Hz), 7.7
(s, H), 7.9 (d, 2H, 8.4 Hz), 8.0 (d, 2H, J = 9.0 Hz), 10.4 (s, H). Anal. calc. for
C22H16N2O4S·0.25 H2O : C, 65.33; H, 3.99; N, 6.93; Found : C, 64.61; H, 4.07; N, 6.85.

4.

Functional Studies to Determine the Binding Affinity of PPAR-γ Receptor
Modulators.
To determine, whether the synthesized compounds are capable of binding to PPAR-γ

LBD and their binding affinity, we performed functional studies by using a fluorescencebased competitive binding experiment.

A. Assay Mechanism:
A fluorescence-based competitive binding assay is used to determine relative affinity
of the test compounds for the PPAR-γ LBD as shown in Figure 9. This is a technique
specially applied to study molecular interactions. In this assay, PPAR-γ LBD is added to
Fluormone™ PPAR-γ Green to form a PPAR-γ LBD/Fluormone™ PPAR-γ Green
complex.
36

Figure 9. Fluorescence based affinity binding assay. NR: nuclear receptor and F is fluorescent ligand.

The binding of PPAR-γ LBD to the Fluormone ligand results in high polarization
value. This complex is then added to individual test compounds in microwell plates.
Competitors or test compounds displace the Fluormone ligand from the PPAR-γLBD/Fluormone complex, causing the Fluormone ligand to tumble rapidly during its
fluorescent lifetime, resulting in a low polarization value. Non-competitors will not
displace the Fluormone ligand from the complex, so the polarization value remains high.
The shift in polarization value in the presence of test compounds is used to determine the
relative affinity of test compounds for PPAR-γ LBD.
B. Assay Procedure:
The PPAR-γ LBD receptor binding assay kits (Panvera, Madison, WI) were used to
determine the ability of the test molecules to displace the fluormone, PPAR Green, from
PPAR-γ LBD/ fluormone PPAR Green complex. Serial dilutions of each test molecule
were prepared in DMSO. The recombinant PPAR-γ LBD (1.1 pM) was pre-incubated with
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PPAR Green (2.5 nM) in screening buffer. After the pre-incubation, the test and PPAR-γ
LBD/ Fluormone ligand complex solution were added into 384-well plate to produce a
final volume of 40 μL per well. The reaction was incubated at room temperature for 2 hrs
and polarization values were measured by using fluorescence microplate reader, Polarion
(Tecan Research, Triangle Park, NC) with excitation wavelength 495 nm and emission
wavelength 535 nm. Fluorescent polarization is measured in mP, a polarization unit. The
formation of PPAR-γ LBD/ Fluormone ligand complex results in highest mP value and is
considered as 0 % inhibition value. Hence mP value and % inhibition value are inversely
proportional to each other. Addition of ligand to PPAR-γ LBD/ Fluormone ligand complex
results in lower mP value and higher % inhibition values. The polarization value versus
test compound concentration curves was analyzed by Sigma Plot software to generate IC50 values.
For the intensities, the actual polarization values P (in mP values) were calculated by
using the following formula:

P = I║ - I ┴ / I ║+ I ┴

Where P is polarization unit, we measure polarization in mP values.
I ║ = intensity parallel.
I ┴ = intensity perpendicular.
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5.

Structural studies of PPAR-γ LBD in complex with PPAR-γ receptor
modulators.
X-ray crystallography was used to elucidate the binding modes of these synthesized

compounds to PPAR-γ LBD. Hanging drop vapor diffusion method (shown in Figure 10)
was used for the crystallization experiments. In the experiment, a droplet of purified
protein, buffer and precipitant is allowed to equilibrate with a larger reservoir containing
similar buffer and precipitant in higher concentrations.

Figure 10. Protein crystallization: Hanging drop vapor diffusion method. Reservoir solution (blue) usually
contains buffer and precipitant. Protein solution (red) contains the same compounds, but in lower
concentrations. The protein solution may also contain trace metals or ions necessary for precipitation of
particular proteins. 88

A. Crystallization of Complex
Crystallization of PPAR-γ LBD with various active compounds was carried out using
excess of the ligand. Rosiglitazone, compound A and B were dissolved in dimethyl
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sulfoxide (DMSO), and were added to the protein (15 mg/mL) solution at a 10:1 molar
excess to encourage complete binding, and then incubated on ice for 1 hour prior to
crystallization trials. Initial crystallization trials for the His-tagged PPAR-γ LBD in
complex with the ligands were conducted using the Crystal screening kit I and II (Hampton
Research) at 4°C, 15°C and room temperature (25°C). We obtained micro-crystals in
previously established crystal conditions as shown below.62, 89, 90
1.4 M Sodium Citrate (pH 5.6), 100 mM HEPES (pH 7.5).
1. 1.4 M Sodium Citrate (pH 5.6), 20 mM tris HCl (pH 8.0).
2. 4.0 M Sodium Formate.
Following, we optimized these conditions to obtain X-ray quality crystals. First, we
optimized the condition 1 above. The crystallization drop was set up using protein (15
mg/ml in 50mM NaCl, 25 mM Tris-HCl, pH 8.0, 5mM DTT), and a reservoir solution of
1.0 - 1.5 M Sodium Citrate (pH 5.6), 100 mM HEPES (pH 7.5).
The crystallization condition 2 was also optimized by setting up crystal drop with
varying reservoir solution concentrations from 0.8 M – 1.6 M Sodium Citrate (pH 5.6), 20
mM tris HCl (pH 8.0), at 4˚ C and also at 20˚C. The protein concentration was also varied.
The 3rd crystallization condition which showed the most encouraging results was also
modified. The crystal drop contains 10 mg/ml protein concentration with reservoir solution
consisting of PEG 20,000 (10% - 30%), 0.1 M MES, at 4˚C and 15˚C.
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{CHAPTER III Results and Discussion}

1.

Expression and Purification of PPAR-γ LBD.
The protein was first expressed and purified as the Glutathione S Transferase-tagged

(GST-tagged) fusion protein in order to aid in purification. GST was originally selected as
a fusion moiety because of several desirable properties. First and foremost, when expressed
in bacteria alone, or in fusion, GST is not sequestered in inclusion bodies. Second, GST
can be affinity purified without denaturation because it binds to immobilized glutathione,
which provides the basis for simple purification.
To make the recombinant protein, the pGEX-4T1 vector with fused GST was expressed in
E. coli Rosetta (DE3) cells.

The protein was precipitated using ammonium sulfate

precipitations (up to 65%). Ammonium sulfate precipitated only PPAR-γ, which ensured
the elimination of intrinsic E.coli PK from the protein mixture. The precipitated fraction
was dissolved in 1 X PBS, pH 7.4 and 1 mM DTT containing 1 mM phenylmethylsulfonyl
fluoride and also dialyzed overnight against the same buffer. The dialyzed protein was then
loaded onto the previously equilibrated GST-column with 1 X PBS for purification. After
washing with the 2 column volume 1 X PBS, the GST moiety was removed by digesting
the fusion protein with the help of thrombin (Pharmacia) on the column. Then the cleaved
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PPAR-γ LBD was eluted with the help of elution buffer. The results of PPAR-γ expression
and purification are shown in Table 2. The protein yield was 5mg/L determined using
Bradford assay. The purified enzyme also showed activity in the subsequent PPAR-γ LBD
fluorescent assay. SDS PAGE gel in Figure 11 showed a good protein expression, however
the purified protein still contained contaminants. Subsequently, the impure fraction was
further purified using SEPHADEX 200 column, which did not help to separate the impure
fraction from the pure protein fraction. Thus, the use of GST for making the protein was
not very successful, as the quantities and purity of the PPAR-γ LBD obtained at 32 KDa
were minimal. The process was also cumbersome and expensive.
To overcome this, we decided to use a different vector, pET28a (+) with His-tag
and an alternate method of purification. First, the PPAR-γ LBD cloned in pET28a (+)
plasmid (Novagen) was obtained from our Brazilian collaborators, Dr. Polikarpov and
colleagues, and transferred to competent Rossetta cells (Strat-agene). The attached Nterminal His-tag allowed PPAR-γ LBD’s to be purified by a single step Ni-NTA column
chromatography. Using this approach, the yield of pure PPAR-γ LBD improved
significantly up to 3-fold, typically 15 mg/L. Figure 12 shows the SDS- PAGE gel of the
purified enzyme. Thus expression of the protein in Rosetta cells with the attached His-tag
represents a new simple method providing improved yield for the expression and
purification of PPAR-γ LBD.
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Figure 11. 10% SDS-PAGE gel of PPAR-γ LBD protein purified using the procedure recommended by
manufacturer (Amersham Pharmacia Biotech). Three fractions of protein were run in parallel with molecular
mass standards. Lanes (1) Protein standard (Fermentas), (2) After cell brake GST- bound PPAR-γ LBD, (3)
After ammonium sulfate GST- bound PPAR-γ LBD, (4) protein elution PPAR-γ LBD 1, (5), (6) and (7) are
protein elutions 2, 3 and 4 respectively.

Figure 12. 10% SDS-PAGE gel of PPAR-γ LBD purified protein. Lanes (1) Protein standard (Fermentas),
(2) and (4) are washing, (3) and (5) show varying concentrations of PPAR-γ LBD with attached His tag.
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Table 2. Yield of PPAR-γ LBD protein with two different expression vectors.
Method

Yield (mg/L)

pGEX-4T1 + GST

5

pET 28a (+) + His-tag

15

2. Molecular Modeling to Design PPAR-γ Receptor Modulators.
Our aim was to use the structural features and binding mode of Rosiglitazone as a
starting point to design novel PPAR-γ agonists. A visual analysis of the binding of
Rosiglitazone suggests two possible structural modifications; first to the ether linkage and
second to the hydrophobic side chain. This culminated into two possible classes of
compounds, type-I and type-II compounds. Using SYBYL 7.3, representative molecules of
these two classes (compound A from type-I and B from type-II) were built and energy
minimized. These compounds were manually docked into PPAR-γ LBD (PDB code
2PRG) using TOM and/or COOT. Minimization of the protein residues around the docked
compounds using SYBYL 7.3 yielded several binding orientations. Unexpectedly, none of
the binding orientations with high HINT scores corresponded to the crystallographically
bound Rosiglitazone’s orientation. As a control, we also energy minimized the
crystallographically bound Rosiglitazone (Figure 13) using SYBYL 7.3, and also
unexpectedly the best binding orientation was not consistent with the crystallographically
bound orientation. Based on this, we decided to use the manually fit putative compounds
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based on Rosiglitazone binding for design purpose. Figure 14-17 show hypothetical
binding of our designed type-I and type-II compounds to the PPAR-γ LBD.
As shown in Figure 14 and 15, the thiazolidinedione rings of both compound A and
Rosiglitazone occupy similar position. Like Rosiglitazone the two oxygen atoms of
thiazolidinedione ring of compound A are capable of making hydrogen-bond interactions
with His323 and His449. Secondly, the newly introduced carbonyl oxygen of the amide
linkage in compound A is capable of making additional hydrogen-bond interaction with
Cys285. Thirdly, the hydrophobic chain was positioned in PPAR-γ LBD binding pocket in
the same manner as Rosiglitazone.
In the type-II compounds, in addition to the described interactions observed for
Rosiglitazone, the amide oxygen can also make hydrogen-bond interaction with Cys285.
Also, the increased length of the hydrophobic side chain could make hydrophobic
interactions with Ile281, Met348, Ile341 and Arg288. Our hypothesis is that the type-I and
-II compounds will have higher affinity to the PPAR-γ LBD because of the additional
hydrogen-bond and/or hydrophobic interactions with the protein.
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Figure 13. Rosiglitazone inn crystal structuure with PPAR
R-γ LBD.
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Figure 14. Proposed binding mode of Compound A (type-I compound) docked manually in PPAR-γ LBD.
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Figure 15. Proposed binding mode of compound A (type-I compound) in the PPAR-γ LBD complex.
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Figure 16. Proposed binding mode of compound B (type-II compound) docked manually in PPARγ LBD.

49

Figure 17. Proposed binding mode of compound B (type-II compound) in the PPAR-γ LBD complex.
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3. Synthesis of Potential PPAR-γ Receptor Modulators.
The whole synthesis was divided into three schemes. In scheme 1 we synthesized 4,
which would serve as precursor to scheme 2 and 3 for synthesis of both classes of
compounds.
A. Intermediates
For synthesis of 4, a two step approach was adopted, first by mixing the commercially
available starting core compound, 1 and 2, in the presence of piperidine and acetic acid in
toluene under stirring condition, for 16-18 hrs at room temperature, 3, was obtained. In the
second step of scheme 1, we reduced the nitro compound to amine. To a stirring solution
of 3 in ethanol, we added tin (II) chloride and the mixture heated to reflux for 2-3 hours, to
obtain 4.
B. Synthesis of type-I compounds:
In scheme 2, the type-I compounds were synthesized by using 4 as one of the two
reactants. Synthesis of five type-I compounds were attempted using two different
approaches, however we were only successful in synthesizing two of the compounds,
including A and D. For synthesis of compound A, to a mixture of 4 and triethylamine in
dichloromethane at 0° C, in presence of nitrogen, hydrocinnamoyl chloride or 5 was added
dropwise.
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Scheme 1:
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After stirring at the same temperature for ten minutes, the mixture was further stirred at
room temperature for 2 hr, to obtain compound A. To a mixture of 4 and 6, in DMF, in
presence of nitrogen at room temperature, HOBt and DEC, were added and the mixture
stirred overnight, to obtain compound D.
Along with above synthesized compounds shown in scheme 2, synthesis of three more
type-I compounds G, H, I, was tried, shown in scheme 2. A similar sequence to that
described in scheme 2 for the synthesis of type-I compound D was followed. Although
TLC showed formation of a new entity, NMR analyses for these three compounds were not
consistent with the structures shown below.
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C. Synthesis of type-II compounds:
Synthesis of type-II compounds as shown in scheme 3 followed similar sequence as
described in scheme 2 for the synthesis of type-I compound D. For synthesis of B, DMF
and THF was added to a mixture of 4 and 7, under nitrogen at room temperature, along
with HOBt and DEC and stirred overnight. For synthesis of C and F same reaction
sequence was followed as shown in scheme 3.
We also carried out the synthesis of two other type-II compounds J and K by following
similar sequence we used in synthesis of B, but was unsuccessful as shown in scheme 3.
The reaction product precipitated out, and the crude material was not soluble in any
solvent.
In conclusion, we have been able to synthesize five compounds, A, B, C, D and F out
of ten that we designed. Synthesis of the other five compounds, G, H, I, J and K are
planned in future using alternate synthetic schemes.
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4. Functional Studies to Determine the Binding Affinity of PPAR-γ Receptor
Modulators.
Fluorescent-based competitive binding assay was used to find out whether the
synthesized compounds bind to PPAR-γ LBD, as well as their binding affinities. Parallel
experiments with Rosiglitazone and Troglitazone in our lab were also performed. If tested
compound binds to PPAR-γ LBD, it should competitively displace the Fluormone ligand
from the PPAR-γ-LBD/Fluormone ligand complex resulting in a low polarization value.
Non-competitors will not displace the Fluormone ligand from the complex, so the
polarization value remains high. The shift in polarization value in the presence of test
compounds is used to determine relative affinity of the test compounds for the PPAR-γ
LBD.
Table 3 shows the competitive inhibition of the Fluormone ligand by Rosiglitazone,
Troglitazone, compounds A, B, C, D, and F. Type-I compounds, A and D shows 74% and
54% inhibition respectively, as compared to 89 and 99% for Rosiglitazone and
Troglitazone, respectively. Compound A has IC-50 value of 344 μM, which translates to a
~1900-fold lower affinity compared to Rosiglitazone (IC-50 value 0.178 μM). The IC-50
of compound D was not determined but we expect to behave similarly as A. Type-II
compounds, B, C and F show 98%, 73% and 78% inhibition respectively as compared to
89% of Rosiglitazone. Compound B shows a significant binding affinity to PPAR-γ LBD,
as evidenced by an IC-50 value of 1.3 μM, which is ~ 7-fold lower than Rosiglitazone. The
IC-50s for the rest of the other compounds were not determined, however based on the %
inhibition we speculate that none of them would exhibit higher potency than compound B.
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It seems that type-II compounds may be more potent than type-I compounds. Most
likely, the extra hydrophobic interactions made by type-II compounds with the residues
Ile281, Met348, Ile341 and Arg288 in the PPAR-γ LBD increase their binding affinity to
LBD compared to the type-I compounds.

Table 3. The % inhibition and IC-50 values by using Fluorescent Polarization Assay.

S.N. Compound

% inhibition*

IC50(μM)

1.

Rosiglitazone

89

0.178

2.

Troglitazone

99

—

3.

Compound A

74

344

4.

Compound B

98

1.30

5.

Compound C

73

—

6.

Compound D

54

—

7.

Compound F

78

—

8.

TDD4-73

90

9.85

9.

TDD4-84

32

780

*Compounds used at 25 μM concentration.

Our designed compounds were hypothesized to have higher affinity to PPAR-γ LBD
than Rosiglitazone due to the proposed additional hydrogen-bond interaction with Cys285
and/or hydrophobic interactions with the protein. However, they still show significantly
lower affinity to the protein compared to Rosiglitazone. As shown in Figure 8, there is a
double bond between the thiazolidinedione ring and the benzene ring of the core structure
of our compounds, which is a single bond in Rosiglitazone. Thus, the thiazolidinedione
ring in Rosiglitazone can easily rotate in the binding pocket, which is unlikely with our
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compounds. We note that the two hydrogen-bond interactions between the two carbonyl
oxygens of thiazolidinedione ring and His323 and His449 are the most important for
binding. Therefore, it is most likely that Rosiglitazone with a flexible thiazolidinedione
ring can easily bind to make optimal interactions with both His323 and His449. This is
unlikely in our compounds, where the ring is rigid and fixed at one orientation. We are
currently synthesizing analogs of our compounds with a single bond between the ring and
the benzene. Our hypothesis is that these compounds will result in better binding affinity.

5. Structural Studies of PPAR-γ LBD in Complex with PPAR-γ Receptor
Modulators.
Structure-based drug design is one of the most logical approaches applied in drug
discovery. It integrates information from several fields, such as X-ray crystallography,
molecular

modeling,

synthetic

organic

chemistry,

quantitative

structure-activity

relationship (QSAR) studies, and biological evaluation to identify new lead molecules that
can interact specifically with the target protein structure. This is a cyclic procedure that
refines each stage of discovery. This structural information obtained from X-ray
crystallography enables design of new molecules or ligands, and eventually drugs that
interfere with the binding of natural ligands to the proteins and consequently alter their
biological function.91
X-ray crystallographic study was thus attempted in order to determine the binding mode of
our compounds with the PPAR-γ LBD. Crystallization experiments were conducted in the
absence and presence of Rosiglitazone, type-I and -II compounds. Initially crystallization
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conditions for the His-tagged PPAR-γ LBD complex, were tried using the crystal screening
kit I and II (Hampton Research) at 20°C. Several crystallization conditions were then
optimized further by fine griding around the initial conditions. Also, previously published
crystallization conditions were used for crystallizing the complex. None of these
experiments yielded X-ray quality crystals, and thus we have been unable to determine the
co-crystal structures of these compounds with PPAR-γ LBD.
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{CHAPTER 3 Summary and Conclusion}

At present, there are two marketed TZDs, Rosiglitazone and Pioglitazone, currently
being used as first line treatment of type-II diabetes. There has been report of serious side
effect for Rosiglitazone. A review of the studies of Rosiglitazone led the FDA to conclude
that the medication might increase the risk of heart attacks and angina, but it’s not clear
what the cause is, but there are speculations that this could be due to Rosiglitazone
metabolites. The drug is still being used but with a BOXED warning.
The development of new type-II diabetes drug that work similarly as Rosiglitazone but
with less side effect and possibly with increased potency is much needed and very urgent.
The main goal of the study is to develop a potential TZD agonist with improved activity
and minimal side effects. In this study, PPAR-γ LBD was purified with simple and
efficient method and also resulted in significant yield. Molecular modeling studies helped
in identification of potential PPAR-γ agonists, which were synthesized. These compounds
were designed to make additional hydrogen-bond and/or hydrophobic interaction with the
protein. Our hypothesis is that these additional binding will lead to increase affinity and
perhaps better agonist. For the type-I compounds, containing thaizolidinedione ring and
carbonyl oxygen of the amide bond, their binding affinity were found to be significantly
lower than Rosiglitazone. Type-II compounds have additional hydrophobic ring attached
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with different functional group on it. The binding affinity of these compounds is relatively
higher and better than type-I compounds but still significantly lower than Rosiglitazone.
This unexpected difference in binding affinity between Rosiglitazone and both type-I and
type-II compounds is most probably due to the fact that thaizolidinedione ring in
Rosiglitazone can easily rotate to make optimal interactions with the protein residues
His323 and His449, which are known to be very important for binding affinity and
agonistic activity. This is not the case in our compounds where the double bond between
the thaizolidinedione ring and the benzene makes the thaizolidinedione ring unable to
rotate and perhaps make optimal contact with the residues His323 and His449. Our
collaborators from The Scripps Research Institute (Scripps Florida) are currently testing
our compounds for their agonistic activity. We are also synthesizing analogs of these
compounds with flexible thaizolidinedione ring system. To find out the important
interactions between PPAR-γ LBD and synthesized compounds, crystallization studies
were attempted but failed. Crystallization attempts are ongoing in order to solve the PPARγ LBD structure in complex with our ligands.
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